Heron Therapeutics | HRTX - Operating Expenses


Heron Therapeutics reported $40.55M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
ALKERMES USD 1.75B 1.43B Mar/2026
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
Amarin USD 51.48M 113K Dec/2025
ANI Pharmaceuticals USD 562.3M 344.37M Mar/2026
Anika Therapeutics USD 133.9M 103.93M Mar/2026
Arrowhead Research USD 215M 8.23M Mar/2026
Eisai JPY 215.74B 15.84B Mar/2026
Emergent BioSolutions USD 555.9M 242.7M Jun/2023
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Insmed USD 506.24M 7.31M Mar/2026
Ligand Pharmaceuticals USD 34.35M 5.27M Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Neurocrine Biosciences USD 599.9M 22.3M Mar/2026
Omeros USD 59.16M 20.13M Jun/2024
Pacira USD 172.75M 20.93M Mar/2026
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Surmodics USD 29.51M 274.86M Jun/2025
Ultragenyx Pharmaceutical USD 305M 16M Mar/2026
Veracyte USD 119.99M 3.99M Mar/2026
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026